Surprisingly, GARS not only correlated with the IPS score of PD-1 and CTLA4 but also correlated with the prognosis of lung cancer patients who received PD-1/PD-L1 therapy (Figures 7E–I). The gene discussed is CTLA4; the disease is lung carcinoma.